Mink Therapeutics (INKT) investor relations material

Executive summary

• Annual meeting scheduled for June 17, 2026, to be held virtually, with voting available online, by phone, mail, or during the meeting.

• Stockholders as of April 23, 2026, are eligible to vote on director elections and auditor ratification.

• Proxy materials are distributed via internet access, with options for printed copies and electronic delivery to reduce environmental impact.

• A one-for-ten reverse stock split was effected on January 28, 2025.

Voting matters and shareholder proposals

• Election of three Class II directors (Garo Armen, Barbara Ryan, John Holcomb) for three-year terms expiring at the 2029 annual meeting.

• Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Board recommends voting FOR all nominees and auditor ratification.

• Shareholders may submit proposals for the 2027 annual meeting by December 30, 2026, following specific procedures.

Board of directors and corporate governance

• Board consists of seven members divided into three classes, with annual elections for one class.

• Majority of directors are independent; annual self-evaluations and performance assessments are conducted.

• Three standing committees: Audit and Finance, Compensation, and Corporate Governance and Nominating; an Affiliate Transactions Committee addresses conflicts with Agenus.

• Code of Ethics and Securities Trading Policy updated in 2023; independent directors meet in executive session.